Peptide-Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects

Department of Materials Science and Engineering , Stanford University, Palo Alto, California, United States
Nano Letters (Impact Factor: 13.59). 05/2006; 6(4):669-76. DOI: 10.1021/nl052405t
Source: PubMed


We report the in vivo targeting and imaging of tumor vasculature using arginine-glycine-aspartic acid (RGD) peptide-labeled quantum dots (QDs). Athymic nude mice bearing subcutaneous U87MG human glioblastoma tumors were administered QD705-RGD intravenously. The tumor fluorescence intensity reached maximum at 6 h postinjection with good contrast. The results reported here open up new perspectives for integrin-targeted near-infrared optical imaging and may aid in cancer detection and management including imaging-guided surgery.

Full-text preview

Available from:
    • "Fluorophores are one of the powerful non-invasive imaging probes and are used for visualizing morphological details of bio-species from living cells, tissues and animals with subcellular resolution [1] [2]. However, the spatial resolution is limited by tissue penetration depth because of high absorption and scattering as well as autofluorescence that occurs in biological tissues [3]. To overcome these problems, " biological transparency window " in the near-infrared range at 750-850 nm, called the first near-infrared window (NIR I), not only allows for improved photon penetration through tissue but also minimizes the effects of tissue autofluorescence and light scattering [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have designed and synthesized NaGdF4:Nd3+, Yb3+, Tm3+ magnetic nanophosphors with combined dual-mode downconversion (DC) and upconversion (UC) photoluminescence upon 800 nm excitation. Hexagonal-phase NaGdF4:Nd3+, Yb3+, Tm3+ nanocrystals (NCs) with an average size of 21 nm were synthesized using a solvothermal approach. Nd3+, Yb3+, Tm3+ triple-doped NaGdF4 NCs exhibit a broad range of photoluminescence peaks covering a near infrared first/second window (860–900, 1,000, and 1,060 nm), and visible emission including blue (475 nm), green (520 and 542 nm) and yellow (587 nm) after excitation at 800 nm. A mechanism involving circulation of energy over Gd3+ sublattices as bridge ions and final trapping by the initial activator ions (Nd3+) has been proposed. Penetration depth studies indicate that NIR emission is easily detected even at a large tissue thickness of 10 mm. These paramagnetic nanophosphors demonstrate a large magnetization value of 1.88 emu/g at 20 kOe and longitudinal relaxivity value of 1.2537 mM−1·S−1 as a T 1-weighted magnetic resonance imaging contrast agent. These NaGdF4:Nd3+, Yb3+, Tm3+ NCs are promising for applications in biological and magnetic resonance imaging.
    No preview · Article · Feb 2014 · Nano Research
  • Source
    • "In comparison with other dual-labeled NPs, IO-anti-EGFR-Cy5.5 NPs show excellent biocompatibility, satisfying colloidal stability, and enhanced MR contrast.24 Furthermore, Cy5.5, as one representative NIRF dye, possesses the minimum absorbance spectra in the NIR region,32 and enables characterization of deep diseased tissues.18 Dual-modality magnetic-fluorescent NP, which imparts contrast in both imaging modalities, such as the one described herein, can extend the prospects of MRI-fluorescence imaging, and facilitate information cross-validation and direct comparison between different modalities. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dual-modality imaging combines the complementary advantages of different modalities, and offers the prospect of improved preclinical research. The combination of fluorescence imaging and magnetic resonance imaging (MRI) provides cross-validated information and direct comparison between these modalities. Here, we report on the application of a novel tumor-targeted, dual-labeled nanoparticle (NP), utilizing iron oxide as the MRI contrast agent and near infrared (NIR) dye Cy5.5 as the fluorescent agent. Results of in vitro experiments verified the specificity of the NP to tumor cells. In vivo tumor targeting and uptake of the NPs in a mouse model were visualized by fluorescence and MR imaging collected at different time points. Quantitative analysis was carried out to evaluate the efficacy of MRI contrast enhancement. Furthermore, tomographic images were also acquired using both imaging modalities and cross-validated information of tumor location and size between these two modalities was revealed. The results demonstrate that the use of dual-labeled NPs can facilitate the dual-modal detection of tumors, information cross-validation, and direct comparison by combing fluorescence molecular tomography (FMT) and MRI.
    Full-text · Article · Jan 2014 · International Journal of Nanomedicine
  • Source
    • "QD in vivo imaging was previously reported based on QD-RGD targeting to integrin αvβ3 expressed in tumor angiogenic vessel endothelial cells only for glioblastoma xenografted in the front flank of nude mice.23,24 In this study, we established a HNSCC model by injecting human squamous cell carcinoma cell line BcaCD885 into the right cheek of nude mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular imaging plays a key role in personalized medicine and tumor diagnosis. Quantum dots with near-infrared emission spectra demonstrate excellent tissue penetration and photostability, and have recently emerged as important tools for in vivo tumor imaging. Integrin αvβ3 has been shown to be highly and specifically expressed in endothelial cells of tumor angiogenic vessels in almost all types of tumors, and specifically binds to the peptide containing arginine-glycine-aspartic acid (RGD). In this study, we conjugated RGD with quantum dots with emission wavelength of 800 nm (QD800) to generate QD800-RGD, and used it via intravenous injection as a probe to image tumors in nude mice bearing head and neck squamous cell carcinoma (HNSCC). Twelve hours after the injection, the mice were still alive and were sacrificed to isolate tumors and ten major organs for ex vivo analysis to localize the probe in these tissues. The results showed that QD800-RGD was specifically targeted to integrin αvβ3 in vitro and in vivo, producing clear tumor fluorescence images after the intravenous injection. The tumor-to-background ratio and size of tumor image were highest within 6 hours of the injection and declined significantly at 9 hours after the injection, but there was still a clearly visible tumor image at 12 hours. The greatest amount of QD800-RGD was found in liver and spleen, followed by tumor and lung, and a weak fluorescence signal was seen in tibia. No detectable signal of QD800-RGD was found in brain, heart, kidney, testis, stomach, or intestine. Our study demonstrated that using integrin αvβ3 as target, it is possible to use intravenously injected QD800-RGD to generate high quality images of HNSCC, and the technique offers great potential in the diagnosis and personalized therapy for HNSCC.
    Full-text · Article · Dec 2013 · OncoTargets and Therapy
Show more